BD Announces First Pharma-Sponsored Trial for BD Libertas™ Wearable Injector for Biologic Drugs

BD announces the first pharma-sponsored clinical trial using its BD Libertas™ Wearable Injector technology for biologic drugs. The trial represents a significant advancement in drug-device combination products that provide greater flexibility for patients. The BD Libertas™ Wearable Injector is an innovative, prefilled, patient-ready-to-use drug delivery system designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to over $670 billion by 2030.

Franklin Lakes, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has announced the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. This marks a significant advancement in the drug-device combination products sector, offering greater flexibility for patients and potentially converting infused medications that require hospital visits into more convenient self-injection at home.

The selection of the BD Libertas™ Wearable Injector for this trial follows successful outcomes from over 50 BD-conducted pre-clinical and clinical studies. A device clinical study demonstrated excellent performance, with 100% of participants stating they would likely use the BD Libertas™ Wearable Injector if prescribed [1].

The BD Libertas™ Wearable Injector is an innovative, prefilled, patient-ready-to-use drug delivery system designed to enable delivery of complex biologics via subcutaneous injection. It supports delivery of high-viscosity biologics (up to 50 centipoise), is offered in 2 to 5 mL and 5 to 10 mL configurations, and features a simple "peel, stick and click" mechanism, requiring no end-user filling or assembly [1].

The biologics market is expected to grow to over $670 billion by 2030 [4]. For pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production.

"This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient-friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery" [1].

References:
[1] https://www.prnewswire.com/news-releases/bd-announces-first-pharma-sponsored-clinical-trial-using-bd-libertas-wearable-injector-technology-for-biologic-drugs-302511241.html
[2] https://www.businesswire.com/news/home/20250515788680/en/Rocket-Pharmaceuticals-Presents-Preliminary-Data-from-Phase-1-Clinical-Trial-of-RP-A601-for-PKP2-Arrhythmogenic-Cardiomyopathy-at-28th-Annual-Meeting-of-the-American-Society-of-Gene-and-Cell-Therapy
[3] Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). https://www.mordorintelligence.com/industry-reports/biologics-market